Omicron Is Here. Will We Use Our New Covid Drugs Wisely?
The world must not repeat history by making Covid-19 drugs inaccessible.
Build Back Better Act Would Patch Holes in Health Coverage
Taken together, the provisions in the social policy bill represent the biggest step toward universal coverage since the passage of the Affordable Care Act.
Build Back Better Act Would Patch Holes in Health Coverage
Taken together, the provisions in the social policy bill represent the biggest step toward universal coverage since the passage of the Affordable Care Act.
Merck’s Covid Treatment Pill Wins Blessing of F.D.A. Panel
The treatment, known as molnupiravir, could be authorized in the United States within days, and available within weeks, if the F.D.A. follows the committee’s recommendation.
South African Company Nears License to Sell J. & J. Covid Shot Across Africa
The new agreement makes Aspen Pharmacare the first African company to market a Covid vaccine on the continent. But it stops short of allowing Aspen to make the ingredients in the vaccine.
South African Company Nears License to Sell J. & J. Covid Shot Across Africa
The new agreement makes Aspen Pharmacare the first African company to market a Covid vaccine on the continent. But it stops short of allowing Aspen to make the ingredients in the vaccine.
¿Las vacunas funcionan para la variante ómicron?
Una “mezcla tipo Frankenstein” de mutaciones suscita preocupación, pero la variante puede seguir siendo vulnerable a las vacunas actuales. Si no es así, serán necesarias revisiones.
Antiviral Covid-19 Pills Are Coming. Will There Be Enough Tests?
The pills must be given early in the course of infection, which means access to timely, accurate test results will be crucial.
Antiviral Covid Pills Are Coming. Will There Be Enough Tests?
The pills must be given early in the course of infection, which means access to timely, accurate test results will be crucial.
Will the Vaccines Stop Omicron? Scientists Are Racing to Find Out.
A “Frankenstein mix” of mutations raises concerns, but the variant may remain vulnerable to current vaccines. If not, revisions will be necessary.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.